This morning, most investors are going to look into the stocks of those companies that may have come into focus on Monday, and one of the companies that did was SOHM Inc. (OTC:SHMN). It is a nutraceutical, cosmeceutical, and pharmaceutical firm involved in the manufacturing and marketing of generic drugs covering a range of treatment categories. On April 1, the company announced that it had entered into a collaboration with San Diego, California-based Coastar Technologies. Coastar is a leader in the biotech space and best known for its specialization in novel drug delivery systems.
In the new collaboration, SOHM and Coastar would work on the advancement of the genome editing space. It would be accomplished through the use of the red blood cell membrane-derived carriers from Coastar and the genome editing technology named ABBIE (A Binding-Based Integrated Enzyme) from SOHM. In this context, it should be noted that in recent years, genome editing has emerged as a path-breaking activity in the genetic research and therapeutics space. That being said, there have been considerable problems with regards to the safe and efficient delivery of the gene editing tools into the cells.
The collaboration between SOHM and Coastar would seek to tackle that particular challenge. It would aim to do so through the deployment of the deep expertise of Coastar in the development of innovative drug delivery systems and the considerable experience possessed by SOHM in the field of gene editing technologies. In the news release, it was noted that the red blood cell membrane-based carriers from Coastar had demonstrated considerable potential in aiding the delivery of the therapeutics into cells. The carriers had some key advantages, like stability, biocompatibility, and the capability of avoiding the immune system altogether. It could be a good move to keep an eye on SOHM.
 Stock Jun Focus After MoU With Coastar Therapeutics){kind=link}